Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.

Cancer discovery·2025
Same author

Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Invisible in the Metrics of Academic Oncology.

JCO oncology practice·2025
Same author

Takotsubo Cardiomyopathy Due to Diffuse Large B-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.

JACC. Case reports·2025
Same author

Outcomes of MicroPulse<sup>®</sup> Transscleral Laser Therapy Using the Revised MicroPulse P3<sup>®</sup> Delivery Device.

Journal of current glaucoma practice·2025

Related Experiment Video

Updated: Jun 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K

Redefining Available Therapy in Oncology Accelerated Approval Decisions.

Shruti Rajesh Patel1, Maya Ramachandran1, Angela Ai2

  • 1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|October 25, 2024
PubMed
Summary

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence should consider prior drugs when evaluating new follow-on cancer therapies. This ensures comprehensive assessment for improved patient outcomes.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: Jun 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Area of Science:

  • Oncology
  • Pharmaceutical Policy
  • Drug Approval Process

Background:

  • Follow-on drugs offer alternatives to existing cancer treatments.
  • The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) evaluates new cancer therapies.
  • Current FDA guidelines may not fully account for the impact of prior drugs on follow-on approvals.

Purpose of the Study:

  • To examine whether the FDA Oncology Center of Excellence should consider previously approved drugs when evaluating follow-on cancer therapies.
  • To assess the implications of prior drug data for the rapid approval pathway.

Main Methods:

  • Review of FDA approval pathways for follow-on oncology drugs.
  • Analysis of case studies involving prior drug considerations.
  • Examination of regulatory science principles in drug evaluation.

Main Results:

  • Prior drug data can significantly inform the efficacy and safety assessment of follow-on therapies.
  • Considering previous drugs may enhance the precision of risk-benefit analyses.
  • The current framework may benefit from explicit integration of prior drug information.

Conclusions:

  • The FDA Oncology Center of Excellence should incorporate the recognition of prior drugs into its evaluation of follow-on oncology medications.
  • This approach can lead to more informed regulatory decisions and potentially better patient care in oncology.